Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study).
J Eur Acad Dermatol Venereol
; 32(9): 1507-1514, 2018 Sep.
Article
en En
| MEDLINE
| ID: mdl-29444376
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Psoriasis
/
Fármacos Dermatológicos
/
Anticuerpos Monoclonales
Tipo de estudio:
Clinical_trials
/
Observational_studies
Límite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Año:
2018
Tipo del documento:
Article